Antibodies face Alzheimer’s reality

The makers of the Alzheimer’s disease antibody treatment Leqembi (lecanemab) have convinced regulators in the US to upgrade its status to full approval, based on further trial data received after the anti-amyloid antibody was granted accelerated approval in January.

This means the drug may now be made available through the US’s national Medicare healthcare scheme, while other insurance providers will make their own judgements about whether and how they cover it.